⚡ Quick Start — If You Read Nothing Else
The 10 most important things to know right now.
- Endometriosis is real, common, and not in your head. Tissue similar to the lining of the womb grows in places it should not — on the pelvic lining, the ovaries, and sometimes the bowel or bladder. It affects roughly 1 in 10 women and girls of reproductive age (about 190 million people worldwide). The pain is a genuine physical problem, even when scans look "normal."
- You usually do not need surgery to get a diagnosis anymore. Modern guidelines support diagnosing endometriosis from your symptoms plus an ultrasound or MRI, and starting treatment without first doing a laparoscopy (keyhole surgery). This change exists to shorten the long delays — often 7–10 years — that people used to face.
- First-line treatment is simple and effective for many. Anti-inflammatory painkillers (NSAIDs) plus a hormonal treatment — the birth-control pill taken continuously, a progestin like dienogest, or the hormonal IUD — quiet the tissue and control pain for a large share of people. These are safe to use for years.
- Newer pills target the disease's hormones precisely. "GnRH-antagonist" pills (elagolix; relugolix combination therapy) lower estrogen to control pain and include or are paired with built-in "add-back" hormones to protect your bones and reduce hot flashes — an advance over the older monthly injections.
- Hormonal treatment does NOT help you get pregnant — it prevents pregnancy. This is the single most misunderstood fact about endometriosis. If you are trying to conceive, fertility is handled on a separate track: surgery in selected cases and, very effectively, IVF.
- Expert surgery can give lasting relief. Skilled keyhole excision (cutting disease out) — including complex deep disease handled by a multidisciplinary team — can substantially reduce pain and, in selected cases, improve the chance of pregnancy.
- A hysterectomy is not a guaranteed cure. Removing the uterus can help some people, especially when adenomyosis is also present, but if endometriosis tissue is left behind elsewhere, pain can continue. Complete removal of the disease matters more than removing the uterus.
- Pain that lasts can have more than one cause. After years of pain, the nervous system and pelvic-floor muscles can become part of the problem ("central sensitization"). Pelvic-floor physical therapy and multidisciplinary pain care genuinely help when removing lesions is not the whole answer.
- The disease stage does not match the pain. Someone with "mild" (Stage I) disease can have severe pain; someone with "severe" (Stage IV) disease can have little. Your treatment is guided by your symptoms and goals, not by a stage number alone.
- This is controllable, not yet curable — and care has improved dramatically. With an individualized, long-term plan at an experienced center, the great majority of people can control pain, protect fertility, and reclaim quality of life.
Your Action Clock — a simple, dated plan to bring to your clinician
Use this as a checklist. It equips you to ask the right questions at the right time; it does not replace your clinician's advice. Timing is individual — these are typical checkpoints drawn from the ESHRE 2022 Endometriosis Guideline.
- Now (this week): Start a pain-and-cycle diary — rate pain 0–10, note what it stops you doing, and how it tracks your period. You do NOT necessarily need surgery to be diagnosed: modern guidelines support starting treatment from your symptoms plus a scan. Ask about a first-step plan of an NSAID plus a first-line hormonal treatment, and, if deep disease is suspected, a referral to an endometriosis specialist center. Ask: "Based on my symptoms and my scan, can we start treatment now without surgery to confirm it first?"
- Within the first week of any new hormonal medicine: Note side effects and any red-flag symptoms; light irregular spotting early on is common and usually settles. Ask your doctor: "Which side effects are expected, and which ones mean I should call you right away?"
- In the first month: Keep the diary going. The first few weeks can bring bleeding or side effects that then settle, so do not judge the treatment yet — give it a fair trial.
- By month 3 (reassess the trial): Hormonal treatments often take about 3 months to show their full effect. If your pain is not controlled after an adequate 3–6 month trial, this is the point to discuss switching options, excision surgery, or a GnRH-class medicine with add-back. Ask: "If I try a hormonal treatment, how long is a fair trial before we decide it isn't working, and what is plan B?"
- If you and your clinician choose a GnRH medicine (elagolix/Orilissa, relugolix combination/Myfembree, or leuprolide/Lupron): confirm the bone-protection plan up front, because these lower estrogen and can thin bone over time. Ask: "What is my add-back plan, how long can I stay on this medicine, and when will my bone density (DXA) be checked?"
- Before any ovarian surgery or years of hormonal treatment (if fertility matters to you): your options stay open only if you plan ahead. Ask: "Should we check my egg reserve and discuss freezing eggs or embryos before we go ahead?"
Understanding Endometriosis
Endometriosis (en-doh-mee-tree-OH-sis) is a chronic condition in which tissue similar to the lining of the uterus (the endometrium) grows outside the uterus. These growths are called lesions, implants, or nodules. They most often sit on the lining of the pelvis (the peritoneum), on the ovaries, and on the ligaments behind the uterus, but they can also involve the bowel, bladder, or the tubes that drain the kidneys (ureters).
Like the lining of the womb, this misplaced tissue responds to the monthly hormone cycle — it builds up, breaks down, and bleeds. But because it has no way to leave the body, it causes inflammation, irritation, scarring, and adhesions (bands of scar tissue that can stick organs together). The result is pain and, for some, difficulty getting pregnant.
The three types (phenotypes)
Doctors describe three main patterns, and a person can have more than one at the same time:
- Superficial peritoneal endometriosis — flat or shallow implants on the pelvic lining. This is the most common type (around 80% of cases).
- Ovarian endometriomas ("chocolate cysts") — cysts on the ovary filled with old, dark blood. They can affect the ovary's egg supply.
- Deep infiltrating endometriosis (DIE) — nodules that grow more than about 5 mm beneath the surface, often behind the uterus, on the uterosacral ligaments, the bowel wall, the bladder, or the ureters. This is the type most likely to need complex, expert surgery.
What it feels like
The most common symptoms are:
- Painful periods (dysmenorrhea) that interfere with daily life — not the mild cramps that a painkiller fixes.
- Chronic pelvic pain that can occur outside your period, too.
- Deep pain with sex (dyspareunia), felt deep inside rather than at the entrance.
- Painful bowel movements (dyschezia) or painful urination (dysuria), often worse around your period.
- Heavy or irregular bleeding, fatigue, and bloating ("endo belly").
- Difficulty getting pregnant (infertility) — sometimes the first sign.
🤝 A note for caregivers and partners
The most powerful thing you can do is believe the pain. Endometriosis pain is invisible and has historically been dismissed — by schools, workplaces, and even clinicians. Validation is not just kindness; it changes outcomes, because people who feel believed are more likely to keep seeking and sticking with care. Throughout this guide you will see caregiver notes flagged like this one, with practical ways to help.
Diagnosis & Understanding Your Disease
The biggest recent change in endometriosis care is how it is diagnosed. You no longer always need an operation to be told you have it.
How a clinician puts the picture together
- Your story. The pattern of your pain — painful periods that worsen over time, pain outside your period, deep pain with sex, painful bowel movements or urination around your period, and any trouble conceiving — is the most important clue.
- Examination. A gentle pelvic exam may reveal tenderness, nodules behind the uterus, or a fixed (non-mobile) uterus suggesting adhesions. A normal exam does not rule endometriosis out.
- Transvaginal ultrasound (TVUS). A specialized pelvic ultrasound is the first-line scan. In experienced hands it reliably detects ovarian endometriomas and many signs of deep disease (such as nodules behind the uterus or involvement of the bowel). It often cannot see superficial disease — so a normal scan does not mean you are fine.
- MRI. Magnetic resonance imaging is used to map deep disease before surgery — for example, how far a bowel or bladder nodule extends — and to look for adenomyosis (see below).
- There is no reliable blood test. A blood marker called CA-125 can be raised in endometriosis but is not accurate enough to diagnose or rule it out. Be cautious of any clinic selling a "simple blood test for endometriosis"; as of 2026 none is validated for routine diagnosis.
Understanding what your scan shows
Ask to have your imaging explained in plain terms. Useful things to learn:
- Do I have an ovarian endometrioma (chocolate cyst)? On which ovary, and how big?
- Is there any sign of deep disease — for example behind the uterus, on the bowel, bladder, or ureters?
- Is there any sign of adenomyosis in the wall of the uterus?
- Is anything "stuck" together (adhesions), such as the ovary fixed to the pelvic wall or the uterus pulled backward?
🤝 Caregiver note — the appointment that finally names it
Diagnosis can bring a complicated mix of relief ("I knew something was wrong") and grief ("why did it take so long?"). Both are valid. Offer to come to the appointment, take notes, and afterward help write down the plan and the next steps so nothing is lost in the emotion of the moment. If a clinician dismisses long-standing, life-limiting period pain as normal, it is reasonable to ask for a referral to a gynecologist or an endometriosis center.
Pain Relief & Hormonal Treatments
For most people, the first plan combines a painkiller for the symptom with a hormonal treatment that quiets the disease itself. The goal is to control pain, reduce or stop periods (since periods drive the pain), and use the gentlest effective option for as long as you need it.
Step 1 — Pain relievers (NSAIDs)
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen are usually the first step for period and pelvic pain. They work best taken regularly around the time pain is expected, rather than waiting for it to peak. They are not a long-term solution on their own and can irritate the stomach or kidneys with heavy use, so they are almost always combined with a hormonal treatment. Acetaminophen (paracetamol) can be added. Opioids are generally avoided for long-term endometriosis pain because they work poorly for this kind of pain and carry real risks.
Step 2 — First-line hormonal treatments
These are effective, well tolerated by many people, and safe to use for years. None of them is "stronger" than the others for everyone — the right choice depends on your symptoms, your contraception and pregnancy plans, side-effect profile, and preference.
| Option | How it helps | Good to know |
|---|---|---|
| Combined hormonal contraceptives (the pill, patch, or ring), often taken continuously to skip periods | Steadies hormones, thins the tissue, and reduces or stops periods — fewer periods usually means less pain. | Familiar, inexpensive, also provides contraception. Continuous (back-to-back) use is often more effective for pain than the traditional stop-start cycle. Not suitable for everyone (e.g., certain migraine or clot-risk situations). |
| Progestins — e.g., dienogest (2 mg daily), norethindrone (norethisterone) acetate, or depot medroxyprogesterone (an injection) | Progesterone-like hormones that suppress the tissue and usually reduce or stop periods. | Dienogest is specifically studied for endometriosis and is a guideline favorite in Europe, Japan, and many countries (see International Access for its US status). Common effects: irregular spotting, mood changes, weight change. The depot injection can lower bone density with long use. |
| Levonorgestrel intrauterine device (LNG-IUD) — the hormonal coil | Releases a small amount of progestin directly into the uterus, often making periods very light or absent and easing pain — especially helpful when adenomyosis coexists. | Lasts several years, low whole-body hormone exposure, also contraceptive. Irregular bleeding is common in the first months. |
Step 3 — GnRH-antagonist and GnRH-agonist medicines (for pain that does not settle)
If first-line hormones do not control your pain, the next class lowers estrogen more deeply. Because very low estrogen causes menopausal-type effects (hot flashes) and, over time, bone thinning, these medicines are given with "add-back" hormones — a small, protective dose of estrogen and a progestin — and are used for defined periods with bone monitoring.
| Medicine | Type / how taken | Add-back & key points |
|---|---|---|
| Elagolix (brand Orilissa) | GnRH antagonist; a pill, once or twice daily. FDA-approved for endometriosis pain since 2018 (US, Canada, Israel). | Taken on its own (no built-in add-back). The lower dose (150 mg once daily) can be used up to 24 months; the higher dose (200 mg twice daily) is limited to 6 months because of bone loss. Side effects: hot flashes, headache, mood changes, and possible effects on liver tests and cholesterol. |
| Relugolix combination therapy (brand Myfembree in the US; Ryeqo in Europe/UK) | GnRH antagonist with built-in add-back (relugolix 40 mg + estradiol 1 mg + norethindrone acetate 0.5 mg) in one daily pill. FDA-approved for endometriosis pain since 2022 (up to 24 months); EU/UK approved for people who have already had treatment for endometriosis. | The all-in-one design keeps bone loss small (on average under 1% at a year), though bone monitoring is still advised. Side effects: hot flashes, headache, mood changes, irregular bleeding. |
| Linzagolix (brand Yselty) | GnRH antagonist pill. Approved in the European Union (since Dec 2024) for endometriosis symptoms in people who have had previous treatment; taken with add-back. Not FDA-approved in the US. | Adds another oral option in Europe. Same principles: add-back to protect bone, defined duration, monitoring. |
| Leuprolide (Lupron Depot) and other GnRH agonists | An injection (monthly or every 3 months). Long-established for endometriosis pain. | Causes a temporary menopause-like state. Used with add-back (commonly norethindrone acetate, sometimes plus low-dose estrogen) to protect bone and reduce hot flashes. Duration is limited and bone density is monitored (a DXA scan) with longer use. |
Medication Dose Reference — typical doses your clinician may use
For information only — your clinician sets your dose, and yours may differ. The doses below are typical adult doses drawn from FDA prescribing information (via DailyMed) and the ESHRE 2022 Endometriosis Guideline, reviewed July 2026. Always follow your own prescription.
| Medicine | Typical dose | Source |
|---|---|---|
| Ibuprofen (NSAID) | 400 mg to 600 mg every 6 to 8 hours with food, ideally started 1 to 2 days before your period | OTC label; ESHRE 2022 |
| Naproxen (NSAID) | 250 mg to 500 mg twice daily with food | FDA label; ESHRE 2022 |
| Combined pill (taken continuously) | One tablet daily, skipping the placebo week so periods are reduced or stopped | ACOG guidance; ESHRE 2022 |
| Dienogest (Visanne) | 2 mg once daily | Visanne prescribing information; ESHRE 2022 |
| Norethindrone (norethisterone) acetate | 5 mg once daily, sometimes increased under guidance | FDA label (per DailyMed) |
| Depot medroxyprogesterone (DMPA) | 104 mg under the skin or 150 mg into muscle every 3 months | Depo-Provera FDA label |
| Levonorgestrel IUD (Mirena) | 52 mg device, replaced about every 5 to 8 years | Mirena FDA label |
| Elagolix (Orilissa) | 150 mg once daily (allowed up to 24 months) OR 200 mg twice daily (limited to 6 months because of bone loss) | Orilissa FDA label, 2018 |
| Relugolix combination (Myfembree) | One tablet daily containing relugolix 40 mg + estradiol 1 mg + norethindrone acetate 0.5 mg (up to 24 months) | Myfembree FDA label, 2022 |
| Linzagolix (Yselty, Europe) | 200 mg once daily with add-back (estradiol 1 mg and norethindrone acetate 0.5 mg) | Yselty EMA label, 2022 |
| Leuprolide (Lupron Depot), a GnRH agonist | 3.75 mg into muscle monthly OR 11.25 mg every 3 months, with add-back | Lupron Depot FDA label |
| Add-back with a GnRH agonist | Norethindrone acetate 5 mg daily, sometimes with low-dose estrogen | ESHRE 2022; FDA label |
| Bone-protection basics | Calcium about 1,000 mg to 1,200 mg daily and vitamin D about 800 IU to 1,000 IU daily from diet and supplements | General bone-health guidance |
- Give a fair trial period, then decide. Most hormonal treatments need about 3 months to show their full effect. If pain is not meaningfully better after an adequate 3 to 6 month trial period, that is the signal to switch options rather than continue indefinitely.
- Elagolix duration stop rules (from the FDA label): the 200 mg twice-daily dose must be stopped at 6 months maximum; the 150 mg once-daily dose should not be used beyond 24 months. Ask when your own stop date is.
- Relugolix combination (Myfembree): total treatment is limited to 24 months. When to stop is set in advance, not open-ended.
- Discontinue if your bones are losing density: if a DXA scan shows meaningful bone loss that add-back cannot offset, the medicine is usually stopped or changed.
- Stop elagolix and call your doctor if you develop yellowing of the skin or eyes, dark urine, or severe upper-abdominal pain (possible liver problem).
- Stop any GnRH-class medicine immediately if you become pregnant or think you might be — all of them are contraindicated in pregnancy.
🤝 Caregiver note — helping with medicines and side effects
Hormonal treatment works best taken consistently. You can help by supporting a daily routine (a phone alarm, a pill organizer), tracking symptoms and cycles together so you can both see whether it is working, and watching for side effects worth reporting. For GnRH-class medicines specifically, help manage hot flashes (layered clothing, a cool bedroom), encourage calcium/vitamin D and the prescribed add-back therapy for bone health, and keep an eye on mood — if mood drops noticeably, that is a reason to call the clinician, not to "push through."
Surgery & Fertility
This section covers two things that are often tangled together but should be thought about separately: surgery to treat pain and disease, and fertility care to help you get pregnant. The crucial point — repeated because it is so often misunderstood — is that hormonal treatments do not improve fertility; they prevent pregnancy. Fertility has its own path.
Surgery for endometriosis
Surgery is usually keyhole (laparoscopic), sometimes robot-assisted. The surgeon either cuts the disease out (excision) or destroys it on the surface (ablation). Excision is generally preferred for deeper disease because it removes the lesion fully and provides tissue for diagnosis; for thin superficial disease both can work. When surgery is done by an experienced specialist, it can give substantial and sometimes lasting pain relief.
| Situation | What surgery involves | Key considerations |
|---|---|---|
| Superficial / moderate disease | Excision or ablation of implants and division of adhesions. | Often improves pain; disease can recur over years, so a hormonal treatment is usually continued afterward to lower the chance of recurrence. |
| Ovarian endometrioma (chocolate cyst) | Removing the cyst wall (cystectomy) or, in some cases, draining and ablating it. | Cystectomy controls the cyst well but can reduce the ovary's egg reserve — an important issue if future fertility matters. Surgeon experience and technique matter; sometimes watchful management is wiser, especially before IVF. |
| Deep infiltrating disease (bowel, bladder, ureters) | Complex excision, sometimes including freeing a ureter (ureterolysis), shaving or removing part of the bowel, or repairing the bladder. | Should be done at an experienced center by a multidisciplinary team (gynecologic surgeon plus colorectal and/or urology). Higher benefit but higher risk — mapping the disease with MRI/ultrasound beforehand is essential. |
Is a hysterectomy a cure?
No — not by itself. Removing the uterus (with or without the ovaries) may be considered for severe disease when fertility is no longer desired, and it is particularly helpful when adenomyosis is also present (see Living Well). But endometriosis lives outside the uterus, so if disease is left behind on the pelvis or bowel, pain can persist. The lesson: complete excision of all disease matters more than removing the uterus. Removing the ovaries causes immediate menopause and its own consequences, so that decision is weighed carefully, especially in younger people.
Fertility — a separate, clear path
Many people with endometriosis conceive naturally. For those who struggle, there is an effective, well-mapped route:
- Hormonal suppression does not help — it is contraceptive. So when you are ready to try, the plan changes from "suppress the disease" to "support conception."
- Surgery in selected cases. Removing disease can improve the chance of natural pregnancy for some — but surgery on the ovaries can reduce egg reserve, so the decision is individualized, especially weighing surgery vs. proceeding to IVF.
- Assisted reproduction (IVF). In-vitro fertilization is highly effective for many people with endometriosis-related infertility and is often the most direct route, particularly with deep disease, endometriomas, or when time matters (e.g., age, low egg reserve).
- Fertility preservation. If you face surgery that could affect your ovaries, or you want to delay pregnancy, freezing eggs or embryos beforehand is worth discussing.
🤝 Caregiver note — surgery recovery and the weight of fertility
After laparoscopic surgery, recovery is usually days to a couple of weeks, but shoulder-tip pain from the gas used in surgery, fatigue, and emotional ups and downs are normal. Help with rest, gentle movement, medications, and getting to follow-up. The fertility conversation can be the heaviest part of endometriosis. Infertility carries real grief, and treatment cycles are emotionally and physically draining. The most helpful thing is to follow the person's lead — some want practical problem-solving, others want to be heard without fixing. Avoid "just relax and it'll happen"; it is untrue and stings. Offer to attend appointments and to share the logistical load of IVF (timed medications, monitoring visits).
Chronic Pelvic Pain & Living Well
Sometimes pain continues or comes back even after the lesions have been treated. This does not mean the treatment failed or that the pain is imagined — it means pain in endometriosis can have more than one source. Understanding this opens up effective help that goes beyond surgery and hormones.
Whole-person pain care that genuinely helps
- Pelvic-floor physical therapy. A specialized physiotherapist can release tight pelvic-floor muscles, ease pain with sex and bowel movements, and teach techniques that reduce pain over time. This is one of the most underused and effective tools.
- Nerve-pain medicines. Medicines that calm overactive nerves (such as certain antidepressants used at low dose for pain, or anti-seizure medicines used for nerve pain) can help when central sensitization is part of the picture.
- Multidisciplinary pain programs. Teams combining a pain specialist, physiotherapy, and psychological support (such as cognitive behavioral therapy or pain-focused approaches) treat chronic pain as its own problem.
- Pacing and self-management. Planning activity to avoid boom-and-bust cycles, gentle regular movement, sleep, heat, and stress care all reduce the burden of chronic pain.
Adenomyosis — the close cousin
Adenomyosis is when tissue like the womb lining grows into the muscular wall of the uterus itself. It often coexists with endometriosis and causes heavy, painful periods and a tender, enlarged uterus. It is seen on ultrasound or MRI. Many of the same hormonal treatments help (the hormonal IUD is often particularly useful), and when fertility is no longer desired and symptoms are severe, hysterectomy reliably treats adenomyosis — one situation where removing the uterus is genuinely curative for that problem.
Conditions that often travel with endometriosis
Because they share nerves and overlap in symptoms, these are worth checking for and co-managing:
- Interstitial cystitis / painful bladder syndrome — bladder pain, urgency, frequency.
- Irritable bowel syndrome (IBS) — bloating, cramping, altered bowel habits.
- Pelvic-floor dysfunction — muscle tightness driving pain with sex, sitting, or bowel movements.
Treating only the endometriosis while ignoring a co-existing bladder, bowel, or muscle problem is a common reason pain seems "untreatable." A good evaluation looks for all of them.
Mental health and quality of life
Living with a painful, chronic, often-invisible condition — frequently after years of not being believed — takes a real toll on mood, work, relationships, and identity. Anxiety and depression are more common in people with endometriosis, and that is an understandable response to chronic pain, not a character flaw. Psychological support is part of good care, not a sign that the pain is "all in your head." If you are struggling, tell your clinician; effective help exists.
Lifestyle and complementary measures — honest framing
Many people find that regular gentle exercise, anti-inflammatory eating patterns, heat, stress management, and good sleep help them feel better and cope with pain. These are reasonable to try and generally safe. But be clear-eyed: no diet or supplement has been shown to cure endometriosis or replace medical treatment. If you want to try a supplement or herbal product, tell your clinician — some interact with medications, and "natural" does not mean risk-free. Use complementary measures alongside, not instead of, evidence-based care.
🤝 Caregiver note — supporting chronic-pain care and pacing
Chronic pain is a marathon. Help by supporting pelvic-floor physiotherapy attendance and home exercises, by respecting pacing (a "good day" is not a reason to overdo it and crash), and by understanding that pain levels fluctuate for reasons that are not always visible or explainable. Normalize rest without guilt. Watch for low mood and gently encourage professional support if it appears. And keep validating — "I believe you, and I'm in this with you" is not a small thing.
Support & Resources
This section gathers practical resources: clinical trials, claims that have not held up under testing, where to find specialist care (with a focus on Utah and the Mountain West, plus national and international centers), how access differs by country, a plain-language glossary, and the key sources behind this guide.
Clinical Trials — how to find them and what is being studied
Endometriosis research is international and active, especially for non-hormonal treatments that could control pain without suppressing fertility. Asking about trials is reasonable in any region.
How to search:
- ClinicalTrials.gov (US and global) — search "endometriosis" and filter by "Recruiting" and your location.
- WHO ICTRP (trialsearch.who.int) — a global registry that pulls in trials from many countries.
- EU Clinical Trials Information System (CTIS), UK / ISRCTN, Australia–NZ ANZCTR, and national registries for region-specific studies.
- Ask an endometriosis specialty center directly — many run or know of trials.
Examples of real, registry-listed programs (status changes — always check the registry for the latest):
| Program / drug | Idea being tested | Registry ID & status |
|---|---|---|
| Dichloroacetate (DCA) — "EPiC" / EPiC2 (University of Edinburgh) | A repurposed, non-hormonal drug aiming to correct the abnormal metabolism around lesions and ease pain without affecting hormones or fertility. A feasibility study (EPiC) was completed; a larger placebo-controlled trial (EPiC2) followed. | EPiC: NCT04046081 (Completed). EPiC2: larger randomized trial — verify current registry entry/identifier on ClinicalTrials.gov/ISRCTN. |
| HMI-115 (Hope Medicine) — anti-prolactin-receptor antibody | A first-in-class injection targeting the prolactin receptor; a non-hormonal approach. A proof-of-concept phase 2 trial reported reduced pain without disturbing sex hormones (published 2025); larger trials planned. | Phase 2 program — search "HMI-115 endometriosis" on ClinicalTrials.gov for current studies. |
| Vipoglanstat (Gesynta Pharma) — "NOVA" trial | A non-hormonal anti-inflammatory (mPGES-1 inhibitor) aiming to reduce pain without suppressing hormones or fertility. | NCT07260669 (Phase 2, Recruiting as of 2026). |
| HMI-115 (Hope Medicine) — anti-prolactin-receptor antibody | A first-in-class non-hormonal injection; the Phase 2 proof-of-concept reduced pain without disturbing sex hormones, and a larger Phase 3 program is planned. | Phase 2: NCT05101317 (Completed). Phase 3: NCT07318688. |
| Elagolix (Orilissa) — the trials behind the approval | The Elaris EM-I and EM-II studies (and their long-term extensions) established that this oral GnRH-antagonist pill reduces period pain and non-period pelvic pain. | NCT01620528, NCT01931670 (pivotal); NCT01760954, NCT02143713 (extensions). |
| Relugolix combination (Myfembree) — the SPIRIT program | SPIRIT 1 and SPIRIT 2 established the once-daily relugolix + estradiol + norethindrone tablet for endometriosis pain, with a 2-year extension confirming durability. | NCT03204318, NCT03204331 (pivotal); NCT03654274 (extension); NCT03931915 (Asia). |
| Linzagolix (Yselty) — EDELWEISS program | The EDELWEISS 3 trial supported EU approval of this oral GnRH antagonist for endometriosis pain in people with prior treatment. | NCT03992846 (EDELWEISS 3); earlier studies NCT02778919, NCT03986944. |
Note: A trial being listed does not mean a treatment works — that is exactly what trials are testing. Some of the drugs above are years from approval, and some may not pan out. Trial identifiers were checked on ClinicalTrials.gov in July 2026; statuses change, so re-check the registry.
Failed or De-adopted Therapies — honest answers to things you may read online
You will encounter many claims about endometriosis. Here is where the evidence currently stands on some of them:
| Claim / approach | What rigorous testing shows |
|---|---|
| "A hysterectomy cures endometriosis." | Not reliably. It can cure adenomyosis and help some people, but endometriosis outside the uterus can persist. Complete excision of disease matters more than removing the uterus. |
| "Pregnancy cures endometriosis." | A myth. Symptoms may quiet during pregnancy and breastfeeding because of hormonal changes, but the disease typically returns afterward. Pregnancy is not a treatment. |
| "You should just have a baby now to fix it." | Not medical advice — it is harmful pressure. Family planning is a personal decision and is not a cure. |
| P2X3 nerve-blocker pills (eliapixant, gefapixant) | Tested for endometriosis pain and did not show meaningful benefit; the eliapixant study (SCHUMANN) was stopped early over a liver-safety concern. These are not endometriosis treatments. |
| "A simple blood test can diagnose endometriosis." | As of 2026, no blood biomarker (including CA-125) is accurate enough for routine diagnosis. Be wary of clinics marketing one. |
| Special "endo diets" or supplements as a cure | No diet or supplement has been shown to cure endometriosis or replace medical care. Some may help you feel better as part of overall well-being, but treat cure claims with skepticism, and check supplements with your clinician for interactions. |
| Long-term opioids for endometriosis pain | Largely de-adopted for this kind of chronic pain — poor effectiveness and real risks. Multidisciplinary pain care is preferred. |
Specialty Center Directory
Phone numbers and services change — confirm before relying on them. Inclusion here is informational, not an endorsement, and availability of specific services varies.
Mountain West & Utah
- University of Utah Health — Obstetrics & Gynecology / Minimally Invasive Gynecologic Surgery (MIGS), Salt Lake City. Diagnosis and comprehensive management including complex/deep-disease excision, chronic-pelvic-pain care, and clinical trials. Main scheduling: 801-581-2897.
- University of Utah Health — Utah Center for Reproductive Medicine (UCRM). Fertility evaluation, IVF, and fertility-preservation counseling for people with endometriosis. 801-581-3834.
- Intermountain Health — Women's Health / Gynecology services across the Wasatch Front and Utah. Hormonal management, surgery, and pelvic-pain care. Find a provider: intermountainhealthcare.org or 866-431-9355.
- Pelvic-floor physical therapy & multidisciplinary pelvic-pain programs (University of Utah and Intermountain) — physical therapy, pain management, and behavioral support for chronic pelvic pain.
US National centers of excellence (examples)
- Mayo Clinic (Rochester, MN; Phoenix, AZ; Jacksonville, FL) — complex endometriosis and multidisciplinary surgery. 507-284-2511.
- Cleveland Clinic — Center for Endometriosis (Cleveland, OH). 216-444-6601.
- Brigham and Women's Hospital / Boston Center for Endometriosis (Boston, MA). 617-732-5500.
- University of California San Francisco (UCSF) — endometriosis and chronic pelvic pain. 415-885-7788.
- Johns Hopkins (Baltimore, MD) — gynecology and reproductive medicine. 410-955-5000.
Veterans (VA)
- George E. Wahlen Department of Veterans Affairs Medical Center (Salt Lake City) — Women's Health, including endometriosis care for veterans. 801-582-1565. Ask about the Women's Health Program and a Women's Health Primary Care Provider.
- Other VA facilities have Women's Health Programs; eligible veterans can ask about gynecology referral and, where relevant, community care. Service-connection for gynecologic conditions may affect coverage — ask your VA patient advocate.
Canada
- BC Women's Centre for Pelvic Pain & Endometriosis (Vancouver). Multidisciplinary care.
- Toronto / University Health Network and academic centers across provinces offer endometriosis surgery and fertility care.
- Coverage note: Provincial health plans cover medically necessary surgery and many treatments; drug coverage varies by province and private insurance, and some newer GnRH-antagonist medicines may require special authorization. IVF funding differs sharply by province.
International (examples of major centers)
- UK: NHS endometriosis specialist centres (accredited for complex disease), e.g., in Edinburgh, Oxford, London, and elsewhere.
- Europe: University endometriosis centers across France, Germany, Italy, Spain, and others (often certified by national/European endometriosis networks).
- Australia/NZ: Specialist endometriosis clinics; Australia has a national endometriosis action plan.
International Access & Regulatory Landscape
The core approach to endometriosis is broadly agreed worldwide, but access to specific newer medicines and to specialized surgery and IVF differs by country. Here is the status of the GnRH-antagonist medicines as of 2026:
| Medicine | United States (FDA) | Europe (EMA) & UK | Other |
|---|---|---|---|
| Elagolix (Orilissa) | Approved for endometriosis pain (2018). | Not approved for endometriosis in the EU/UK. | Approved in Canada and Israel. |
| Relugolix combination (Myfembree / Ryeqo) | Myfembree approved for endometriosis pain (2022), up to 24 months. | Ryeqo approved in the EU (2023) and UK (2025) for people with a history of prior endometriosis treatment. | Relugolix is also approved/used in Japan in women's-health and other indications. |
| Linzagolix (Yselty) | Not FDA-approved for endometriosis (or fibroids) in the US. | Approved in the EU (Dec 2024) for endometriosis symptoms in people with prior treatment; available via NHS in England (2025). | Approved for fibroids in some markets (e.g., Taiwan, 2025). |
| Dienogest (Visanne / Dinagest, 2 mg) | Dienogest monotherapy for endometriosis is not separately FDA-approved in the US (dienogest is available in the US only inside certain combined contraceptive pills). | Widely approved and commonly used across Europe. | Very widely used in Japan and many Asian countries as a first-line endometriosis treatment. |
Education & peer support
- Endometriosis Foundation of America — endofound.org (education, awareness, events).
- American College of Obstetricians and Gynecologists (ACOG) patient resources — acog.org.
- World Endometriosis Society and national societies — clinical information and links to specialists.
- ClinicalTrials.gov and WHO ICTRP — trial listings.
- Reputable patient communities can offer connection and practical tips — just cross-check medical claims with your clinician.
Key References & Sources
This guide draws on major international guidelines, pivotal clinical trials, and regulatory documents, including:
- ESHRE Endometriosis Guideline (2022) — European Society of Human Reproduction and Embryology (clinical diagnosis, first-line hormonal therapy, GnRH therapy, surgery, fertility).
- NICE guideline NG73 (UK) — Endometriosis: diagnosis and management.
- ACOG and ASRM guidance and statements (US) on endometriosis, chronic pelvic pain, staging, and fertility.
- Elagolix: Taylor HS et al., "Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist," NEJM 2017;377:28–40 (Elaris EM-I/EM-II; NCT01620528, NCT01931670). FDA label (Orilissa).
- Relugolix combination: Giudice LC et al., SPIRIT 1 & 2, Lancet 2022;399:2267–2279 (NCT03204318, NCT03204331); 2-year extension, Human Reproduction 2024 (NCT03654274). FDA label (Myfembree); EMA EPAR (Ryeqo).
- Linzagolix: Donnez J et al., EDELWEISS 3, Human Reproduction 2024;39:1208–1221 (NCT03992846). EMA EPAR (Yselty).
- Dichloroacetate: EPiC feasibility study (NCT04046081) and EPiC1 report, Lancet Obstet Gynaecol Women's Health 2025.
- HMI-115: proof-of-concept phase 2 trial (NCT05101317), Lancet Obstet Gynaecol Women's Health 2025; a Phase 3 trial (NCT07318688) is planned.
- Elagolix long-term: Elaris EM-III and EM-IV extension trials (NCT01760954, NCT02143713), reported 2019, supporting up to 12 months of continued treatment (per Orilissa FDA label).
- Relugolix combination in Asia: a Phase 3 trial vs. leuprorelin (NCT03931915), supporting the relugolix program beyond the US SPIRIT studies.
- Linzagolix earlier studies: the Phase 2 dose-finding trial (NCT02778919, EDELWEISS) and the Phase 3 EDELWEISS 2 trial (NCT03986944), informing the EU label (Yselty EMA guidance, 2022).
- Vipoglanstat: the NOVA Phase 2 trial (NCT07260669), an mPGES-1 inhibitor being studied 2025–2026 as a non-hormonal option.
- FDA prescribing information (via DailyMed), reviewed July 2026: Orilissa (elagolix), Myfembree (relugolix/estradiol/norethindrone), Lupron Depot (leuprolide), Depo-Provera, Mirena; EMA labels for Ryeqo and Yselty. Drug prices per GoodRx, accessed July 2026.
This guide is for education only and is not a substitute for professional medical advice, diagnosis, or treatment. Treatments, approvals, and trial statuses change; verify current details with your clinician and official sources. Last reviewed June 2026.
Clinical Trials — how to find them and what is being studied
Ask your care team whether a clinical trial is appropriate for your situation, and search ClinicalTrials.gov for current studies. See also the resources listed elsewhere in this guide.